actually in remission, or still active and being regularly treated over extended periods of time. Do schedule a review examination unless the record clearly shows a not and stable remission. Consider assigning a permanent and total evaluation when a Important: provision under applies. For more information when not to schedule a review Reference: examination, see M21-1, Part III, Subpart iv, 3.B.2.c. Mycosis fungoides is a cutaneous T-cell lymphoma which is a type of l. Considering Claims for SC of lymphoma (NHL). For the purposes of determining SC, the Mycosis disease should be considered the same as NHL and subject to presumptive SC Fungoides under the provisions of as well as SC under . Mycosis fungoides often manifests as skin symptoms including patches plaques, or tumors. Treatment for mycosis fungoides depends on the involvement and staging and can range from topical therapies such as ultraviolet/light therapy, to the requirement for systemic chemotherapy or radiation in advanced stages. If SC for mycosis fungoides was previously denied, the evidence of Note: record at the time of the prior denial shows a diagnosis of mycosis fungoides and confirms the Veteran’s in Vietnam, review the decision in accordance with and take appropriate action to correct the decision. For more information on clear and unmistakable error (CUE) Reference: determinations, see M21-1, Part III, Subpart iv, 2.B.4, and M21-1, Part IV, Subpart ii, 3.A.2. For the purposes of evaluating SC mycosis fungoides, review the medical m. Evaluating Mycosis evidence to identify the manifestations of the disease and/or the treatment Fungoides required. Mycosis fungoides can potentially be evaluated as skin malignancy under , or NHL under . Use the table below to determine whether to evaluate active mycosis fungoides under or .
actually in remission, or still active and being regularly treated over extended periods of time. Do not schedule a review examination unless the record clearly shows a and stable remission. Important: Consider assigning a permanent and total evaluation when a provision under applies. Reference: For more information when not to schedule a review examination, see M21-1, Part III, Subpart iv, 3.B.2.c. l. Considering Claims for SC of Mycosis Fungoides Mycosis fungoides is a cutaneous T-cell lymphoma which is a type of lymphoma (NHL). For the purposes of determining SC, the disease should be considered the same as NHL and subject to presumptive SC under the provisions of as well as SC under . Mycosis fungoides often manifests as skin symptoms including patches plaques, or tumors. Treatment for mycosis fungoides depends on the involvement and staging and can range from topical therapies such as ultraviolet/light therapy, to the requirement for systemic chemotherapy or radiation in advanced stages. Note: If SC for mycosis fungoides was previously denied, the evidence of record at the time of the prior denial shows a diagnosis of mycosis fungoides and confirms the Veteran’s in Vietnam, review the decision in accordance with and take appropriate action to correct the decision. Reference: For more information on clear and unmistakable error (CUE) determinations, see M21-1, Part III, Subpart iv, 2.B.4, and M21-1, Part IV, Subpart ii, 3.A.2. m. Evaluating Mycosis Fungoides For the purposes of evaluating SC mycosis fungoides, review the medical evidence to identify the manifestations of the disease and/or the treatment required. Mycosis fungoides can potentially be evaluated as skin malignancy under , or NHL under . Use the table below to determine whether to evaluate active mycosis fungoides under or .
1-28-16_Key%20Changes_M21-1III_iv_4_SecI.docx